Discovery Pipeline
  • aldosterone synthase inhibitors

    Aldosterone synthase inhibitor is a highly anticipated drug in cardio-metabolic therapy. We develop compounds that selectively inhibit synthesis of aldosterone for future use in therapy of drug-resistant arterial hypertension and non-genomiс effects of high aldosterone. We are the first to fulfill this gap by solving the crystal structure of aldosterone synthase in complex with substrate and inhibitor.

    read more
  • novel anti-tuberculosis drug

    We’ve identified and validated a new targets – mycobacterial cytochromes P450, responsible for cell wall formation and depression of local immune response in human. This achievement is a basis for a drug discovery for treatment of resistant (MDR, XDR) forms of tuberculosis. 

    read more
  • pipeline potential

    Cancer, infections, inflammation, chronic kidney disease are the examples of pipeline extension potential. 

    read more
News and Events
04 June 2018
2018 BIO International Convention in Boston, MA
Target Medicals is participating in largest business partnering event.
01 May 2018
Target Medicals is a tenant of Bayer CoLaborator.
Target Medicals is proud to be among biotech companies selected by Bayer for CoLaborator program.
11 February 2018
Intertational Aldosterone Conference
Our R&D Director is presenting on 43rd Meeting of the International Aldosterone Conference, which will take place in Chicago, March 15-16, 2018.
All news and events